Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Apr 19, 2023 7:37pm
362 Views
Post# 35404121

Lay of the land….

Lay of the land….Onc CMO, Thomas Heineman will be participating in a virtual panel discussion tomorrow @ 9am.
Rules & procedures dictate that if he is to be discussing anything new or not public information, there needs to be a N.R. First.

So, if we don't see any 7am-8am, N.R. He will not be revealing anything " new"
in that context, could be an opportunity to elaborate on existing information & its meaning going forward.

My understanding you need to be a cannacord client to log in.
That in itself is one reason for the N.R. Requirement.

I'd be quite happy to see something tomorrow am.
I need to get up early regardless, would be a great start to the day.
else.? Waiting for next update.
I assume , we know for sure , Q1 update , Friday May 5th @ 8:30.
then ASCO early June.
AGM in there someplace as well.
We do need some excitement.

<< Previous
Bullboard Posts
Next >>